Spruce Biosciences

Spruce Biosciences, Inc operates as a late-stage biopharmaceutical company, which focuses on the development of novel therapies for rare diseases affecting the endocrine system. The firm is initially developing its wholly-owned product candidate, tildacerfont, as the non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia. The company was founded on November 13, 2014 and is headquartered in Daly City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spruce Biosciences reports mixed trial results, eyes Phase III advancement

Spruce Biosciences faces a mixed performance in Phase II trials, with promising results in pediatric CAH patients but challenges in adult populations. Financially, the company is stable with a focus on cost-saving initiatives. Despite setbacks, opportunities exist in advancing tildacerfont for CAH treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It focuses on developing its wholly owned product candidate, Tildacerfont. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences Inc May Have Engaged In Illegal Practices And Affected Investors Are Invited To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

An Inquiry Has Been Launched Into Whether Spruce Biosciences Inc. Violated Securities Regulations And Stockholders Are Encouraged To Assist

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences Inc Is Being Investigated For Fraud And The Schall Law Firm Seeks Investor Participation

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Potential Securities Law Violations By Spruce Biosciences Inc. And Stakeholders Should Reach Out

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences Is Being Inquired Into For Securities Fraud And Investors Are Encouraged By The Schall Law Firm To Take Part

LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Are Invited By The Schall Law Firm To Join An Investigation Into Whether Spruce Biosciences Inc Breached Securities Laws

NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.

Spruce Biosciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SPRB

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences Inc Might Have Committed Securities Law Violations And The Schall Law Firm Seeks Investors To Help

NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.

SPRB ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Spruce Biosciences, Inc.

LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders In Spruce Biosciences Inc Are Encouraged To Contact The Schall Law Firm About Possible Securities Fraud

NEW YORK, NY / ACCESSWIRE / August 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.

Did Spruce Biosciences, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SPRB

LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Spruce Biosciences Inc For Potential Securities Law Violations And Investors Are Urged To Reach Out

NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.

SPRB STOCK ALERT: Levi & Korsinsky Notifies Spruce Biosciences, Inc. Investors of an Ongoing Investigation

LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

An Securities Fraud Inquiry Has Been Opened Into Spruce Biosciences Inc And The Schall Law Firm Seeks Shareholder Participation

NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.

Spruce Biosciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Spruce Biosciences (SPRB)

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors In Spruce Biosciences Inc Are Urged To Join The Schall Law Firm In An Investigation For Possible Securities Law Violations

NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.

Lost Money on Spruce Biosciences, Inc. (SPRB)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholders To Participate In An Inquiry Into Spruce Biosciences Inc For Potential Securities Fraud

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.

Lost Money on Spruce Biosciences, Inc. (SPRB)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Reach Out To The Schall Law Firm About Spruce Biosciences Inc's Possible Violations Of Securities Laws

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.

Investors Who Lost Money on Spruce Biosciences, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - SPRB

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Are Invited To Contact The Schall Law Firm About Spruce Biosciences Inc's Potential Securities Law Violations

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.

Spruce Biosciences, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SPRB

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Encouraged To Reach Out To The Schall Law Firm About Spruce Biosciences Inc's Possible Securities Law Violations

NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.

News for Spruce Biosciences Stock (SPRB)